AstraZeneca

Advances in immunotherapy, including CAR T-cell therapy and bispecific antibodies, have significantly improved treatment for follicular lymphoma (FL), especially for relapsed patients. Axicabtagene ciloleucel (Yescarta) has shown durable remissions. DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report highlights 50+ companies and 55+ therapies in development. Key companies include Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and Johnson & Johnson Innovative Medicine. Promising therapies like Parsaclisib and TQ-B3525 are in various clinical phases. Recent developments include tafasitamab's Phase III success and collaborations for CAR-T therapies.

CAPItello-281 Phase III trial results show AstraZeneca's Truqap (capivasertib) + abiraterone + ADT significantly improves rPFS in PTEN-deficient mHSPC patients, with early OS trend improvement. Trial continues for OS assessment.

AstraZeneca's benralizumab, an IL-5 inhibitor, shows promise in treating acute asthma attacks, potentially revolutionizing care for severe exacerbations. A study by King's College London found benralizumab, used with prednisolone, reduced treatment failure rates from 74% to 45% in patients with high eosinophil levels. This marks a significant advance in asthma treatment.

The 'Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024' report highlights emerging therapies like Brensocatib and HSK31858, which aim to address the underlying mechanisms of NCFB, potentially improving patient quality of life. Key industry players are actively developing these therapies, with significant implications for managing NCFB.

New treatment benralizumab for asthma and COPD, developed by AstraZeneca, shows significant improvements in respiratory symptoms and reduced treatment failures compared to steroids, with fewer side effects. This marks the first new treatment in 50 years.

Six companies—Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, and Wave Life Sciences—are leading in the development of antisense oligonucleotides, a targeted treatment for various diseases. Ionis, a pioneer with over 40 drugs in its pipeline, recently priced a $500 million IPO. Isarna's ISTH0036 targets TGF-β for ophthalmic conditions. Regulus focuses on microRNA targeting with its lead candidate RGLS8429 for ADPKD. Sarepta has three approved PPMO therapies for DMD and a recent $1 billion deal with Arrowhead Pharmaceuticals. Secarna's SECN-15 targets NRP1 for oncology. Wave Life Sciences' WVE-003, for Huntington's disease, recently reported positive phase 1b/2a trial results. The antisense oligonucleotide market is projected to grow to $5,519 million by 2033.

Shuttle Pharma expands Phase II trial of ropidoxuridine for glioblastoma, dosing first cohort at US cancer centers. The trial, combining ropidoxuridine with radiation therapy, aims to treat IDH wild-type, methylation-negative glioblastomas at multiple sites including UVA Cancer Center. Shuttle Pharma CEO Anatoly Dritschilo highlights the strategic alignment with nationally recognized cancer centers to advance the trial.

A new drug, Benralizumab, targets specific white blood cells to reduce lung inflammation, proving more effective than steroids in treating asthma and COPD, leading to fewer treatment failures and hospital visits. The treatment can be administered at home or in a GP practice.

AstraZeneca's AKT inhibitor Truqap showed significant improvement in radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer patients, with an early trend towards overall survival improvement.

A Phase II trial of AstraZeneca’s Fasenra in eosinophilic asthma and COPD exacerbations showed a 45% exacerbation rate with Fasenra vs. 74% with prednisolone, with no fatal AEs. Fasenra was well-tolerated, offering better outcomes than standard care.